ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has earned a consensus rating of “Hold” from the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $65.33.

Several research analysts recently weighed in on ANIP shares. Canaccord Genuity reaffirmed a “buy” rating and set a $60.00 target price on shares of ANI Pharmaceuticals in a research note on Wednesday, August 9th. Guggenheim reaffirmed a “buy” rating and set a $80.00 target price on shares of ANI Pharmaceuticals in a research note on Tuesday, July 4th. BidaskClub raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 18th. Finally, Zacks Investment Research raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 5th.

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of ANI Pharmaceuticals by 8.1% in the 2nd quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock valued at $22,322,000 after purchasing an additional 35,722 shares during the period. First Manhattan Co. boosted its position in shares of ANI Pharmaceuticals by 35.3% in the 2nd quarter. First Manhattan Co. now owns 376,395 shares of the specialty pharmaceutical company’s stock valued at $17,615,000 after purchasing an additional 98,300 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of ANI Pharmaceuticals by 91.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 339,268 shares of the specialty pharmaceutical company’s stock valued at $15,878,000 after purchasing an additional 161,743 shares during the period. Renaissance Technologies LLC boosted its position in shares of ANI Pharmaceuticals by 7.0% in the 2nd quarter. Renaissance Technologies LLC now owns 297,400 shares of the specialty pharmaceutical company’s stock valued at $13,918,000 after purchasing an additional 19,400 shares during the period. Finally, Nomura Holdings Inc. boosted its position in shares of ANI Pharmaceuticals by 0.6% in the 1st quarter. Nomura Holdings Inc. now owns 208,901 shares of the specialty pharmaceutical company’s stock valued at $10,352,000 after purchasing an additional 1,164 shares during the period. Institutional investors and hedge funds own 55.86% of the company’s stock.

Shares of ANI Pharmaceuticals (ANIP) opened at 53.90 on Wednesday. The company has a 50 day moving average of $50.03 and a 200 day moving average of $48.29. ANI Pharmaceuticals has a 52-week low of $42.23 and a 52-week high of $68.61. The stock has a market capitalization of $627.29 million, a price-to-earnings ratio of 117.94 and a beta of 3.05.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.79 by $0.19. ANI Pharmaceuticals had a return on equity of 22.70% and a net margin of 3.35%. The business had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $43.20 million. During the same quarter last year, the business posted $1.11 earnings per share. The company’s quarterly revenue was up 43.0% on a year-over-year basis. Analysts predict that ANI Pharmaceuticals will post $3.84 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/10/11/ani-pharmaceuticals-inc-anip-receives-average-recommendation-of-hold-from-analysts.html.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.